RAPA114 + atorvastatin

RAPA114 + atorvastatin is a combination of two drugs: **RAPA114**, which is an investigational drug (nature and modality not fully defined in available sources), and **atorvastatin**, a well-established HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce cardiovascular risk. The combination has been studied primarily for pharmacokinetic interactions, specifically evaluating the effect of RAPA114 on the pharmacokinetics of atorvastatin in healthy volunteers. There is also preclinical evidence (using rapamycin, which RAPA114 is likely related to, but may not be identical) that combining a rapamycin-analog with atorvastatin may have synergistic benefits in lipid metabolism and atherosclerosis reduction by modulating cholesterol handling and inflammatory cytokines. However, RAPA114 is a separate investigational agent, distinct from rapamycin, and the clinical focus to date is mainly on interaction and safety, not on a marketed, approved therapy or defined clinical indication.[1][2][3]